Study #2023-0680
A phase 1 study of SYNKIR-110, autologous t cells transduced with mesothelin KIR-CAR, in subjects with mesothelin-expressing advanced Ovarian cancer, Cholangiocarcinoma, or Mesothelioma.
MD Anderson Study Status
Enrolling
Treatment Agent
SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Description
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Study phase:
Phase I
Physician name:
Mehmet Altan
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-577-0738
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.